Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genotypic Resistance-guided Triple Therapy Versus Empirical Concomitant Therapy for First-line H. Pylori Eradication.

NCT04090021 is registered in ClinicalTrials.gov with Konstantopoulio-Patission General Hospital of Nea Ionia as lead sponsor.

NCT NCT04090021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04090021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genotypic Resistance-guided Triple Therapy Versus Empirical Concomitant Therapy for First-line H. Pylori Eradication.
Lead sponsor
Konstantopoulio-Patission General Hospital of Nea Ionia
Phase
Phase 4
Overall status
Unknown status
Start date
September 1, 2019
Completion date
February 28, 2020
Enrollment
304 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection